Published 12 hours ago • loading... • Updated 11 hours ago

Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia

On Wednesday, May 6, 2026, Alebund Pharmaceuticals Limited announced completion of patient enrollment in the global Phase 3 pivotal trial for AP301, a novel fiber-iron-based phosphate binder treating hyperphosphatemia.
Hyperphosphatemia affects approximately 95% of dialysis-dependent chronic kidney disease patients, yet existing phosphate binders frequently cause poor compliance due to gastrointestinal side effects and high pill burdens limiting phosphate control.
Dr. Geoffrey A. Block of U.S. Renal Care and Professor Xiaoqiang Ding of Zhongshan Hospital, Fudan University, led the trial enrolling 282 chronic kidney disease patients on maintenance dialysis—138 in the United States and 144 in China.
The FDA designated this trial as the single pivotal study supporting U.S. registration of AP301. Chief Medical Officer Jin Tian called it "an important milestone in the global registrational development of AP301."
By 2035, the global serum phosphorus-lowering product market is forecasted to reach USD 6 billion, while Alebund plans to submit a New Drug Application in China in the near future.

Insights by Ground AI

34 Articles

The Berkshire Eagle

+33 Reposted by 33 other sources

Center

Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia

SHANGHAI, May 6, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced the completion of patient enrollment…

12 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year